Peter Soparkar - 19 Sep 2022 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role
chief Operating Officer and Chief and Chief Legal Officer
Signature
Peter Soparkar, by /s/ Ron A. Metzger, Attorney-in-Fact
Issuer symbol
ADVM
Transactions as of
19 Sep 2022
Net transactions value
-$14,232
Form type
4
Filing time
21 Sep 2022, 19:59:45 UTC
Previous filing
16 Sep 2022
Next filing
03 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADVM Common Stock Sale $14,232 -13,305 -4.6% $1.07 273,251 19 Sep 2022 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of certain performance stock units.
F2 Price reported is a weighted-average sale price. The shares were sold at prices ranging from $1.069589 to $1.0728. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3 Includes 6,000 shares purchased on May 20, 2022 pursuant to the Issuer's 2014 Employee Stock Purchase Plan, as amended and restated.

Remarks:

chief Operating Officer and Chief and Chief Legal Officer